New scan could spot childhood cancer faster

NCT ID NCT07111117

Diagnosis Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study compares a new type of PET/CT scan using 18F-MFBG to the current standard scan (123I-MIBG) in 30 children with relapsed or refractory neuroblastoma. The goal is to see if the new scan works as well or better for detecting tumors. If it does, it could offer a quicker and clearer imaging option for these young patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: 18F-MFBG (a radioactive tracer for PET/CT imaging)
What this could lead to: If successful, this could replace the current standard scan with a faster, more accurate imaging method for children with neuroblastoma.
What could go wrong: This is a small, early-phase study (30 participants) comparing two imaging methods, not testing a treatment. The new scan may not prove superior or practical in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

365 days to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with histologically proven neuroblastoma. 2. Relapsed or refractory neuroblastoma. 3. 123I-MIBG avid neuroblastoma (positive 123I-MIBG scintigraphy = showing at least one neuroblastoma lesion (either primary or metastatic) with a significant avidity for 123I-MIBG), performed within 2 weeks to 2 days prior to 18F-MFBG PET/CT. 4. No specific treatment for neuroblastoma between 123I-MIBG scintigraphy and 18F-MFBG PET/CT (PET/CT shall not delay therapeutic management.) 5. Age ≥ 365 days to \< 18 years old. For children under 13 months, day of birth should be collected. 6. Weight ≥ 9 kg. 7. Performance Status: Lansky or Karnofsky ≥ 60%. 8. Signed written informed consent by the 2 holders of the parental authority or legal representative(s). 9. Patients covered by a health insurance system. Exclusion Criteria: 1. Patient inability to comply with protocol requirements without general anesthesia. 2. Pregnant or breastfeeding patient. If indicated, at the investigator's discretion, patients of childbearing potential should have urinary pregnancy test the day of the PET/CT procedure, prior to the MFBG administration. 3. Any treatment likely to interact with MIBG initiated/modified between scintigraphy with MIBG and PET/CT with MFBG. 4. Patient with a parent or legal representative with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroblastoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

3 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New scan could spot childhood cancer faster

What the study statuses mean